Zeteo Biomedical Joins U.S. Government’s Rapid Response Partnership Vehicle (RRPV)

August 21, 2024 – Austin, TX – Zeteo Biomedical LLC, a leading innovator in nasal and sublingual drug and vaccine delivery devices, has been accepted as a member of the Biomedical Advanced Research and Development Authority (BARDA) Rapid Response Partnership Vehicle (RRPV) Consortium. As part of this prestigious consortium, Zeteo will contribute its advanced delivery device technology and expertise in technical and supply services to expedite the development and distribution of vaccines and medical countermeasures by pharma and biotech partners.

Timothy Sullivan, CEO of Zeteo Biomedical, expressed the company’s enthusiasm about joining the consortium, stating, “We are thrilled to be a part of the RRPV. Zeteo is pioneering needle-free nasal and sublingual delivery devices for drugs and biologics in both liquid and powder forms. Our innovative technology, technical services, fill/finish manufacturing technology and efficient production processes are designed to support the rapid creation, production and deployment of next-generation vaccines and medical countermeasures that protect global populations from infectious threats like Influenza, COVID-19, Monkeypox, #mpox, and other diseases. We are eager to collaborate with BARDA and our consortium partners on this critical initiative.”

About Zeteo Biomedical LLC

Zeteo Biomedical™ is a biomedical device technology company headquartered in Pflugerville, Texas. The company specializes in patient-centric delivery device technology, drug/device combination product development, and fill/finish packaging solutions for pharmaceuticals, biopharmaceuticals, biologics, and botanicals. Their technology applications include drug/device combination products for intranasal, nose-to-brain, ophthalmic, sublingual, and animal care applications. For more information, visit Zeteo’s website.